FIGURE

Fig. 5

ID

ZDB-FIG-230424-25

Publication

Yang et al., 2023 - FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling

Other Figures

All Figure Page

Back to All Figure Page

Fig. 5

Combination of Roblitinib and CPI-169 synergistically inhibits the YAP signaling. A Volcano Plot showed the differentially expressed genes between control group and CPI-169 + Roblitinib treatment group (fold change ? 2 or ? ? 2 and p-values < 0.05). HepG2 cells were treated with CPI-169 + Roblitinib for 48 h, followed by RNA-Seq analysis. Red indicates high relative expression, and blue indicates low relative expression. B Bubble chart showed the KEGG pathway analysis of differentially expressed genes following CPI-169 + Roblitinib treatment in (A). P-values < 0.05 was regarded as statistically significant. C Gene set enrichment analysis (GSEA) showed that the Hippo signaling pathway was enriched in the co-treatment group compared with Control group. D Western bolt detected the expression level of YAP1 and p-YAP1 after CPI-169, Roblitinib or CPI-169 + Roblitinib treatment for 48 h. E Venn diagram showed YAP1 target genes that were regulated by CPI-169 + Roblitinib treatment. F Gene functional annotation of GO enrichment analysis of the 141 down-regulated YAP1 target genes in (E) via Metascape. G Heatmap representing the expression levels of 18 YAP1 target genes related to cell proliferation, cell migration and anti-apoptosis determined by RNA-Seq in HepG2 cells following CPI-169, Roblitinib or CPI-169 + Roblitinib treatment for 48 h. H Genomic tracks displayed ChIP-seq data for YAP1 around the indicated genes and their corresponding RNA-Seq signals in (G). I qPCR analysis of the representative YAP1 target genes from typical pathway related to cell proliferation, cell migration and anti-apoptosis in (G). Data are presented as mean � SEM (n = 3, one-way ANOVA with Tukey?s multiple comparisons test, *P < 0.05, **P < 0.01, ***p < 0.001, ****p < 0.0001, ns, no significance). J Luciferase assay for YAP/TAZ activity in HepG2 and SMMC-7721 cells following CPI-169, Roblitinib or CPI-169 + Roblitinib treatment for 48 h. Data are presented as mean � SEM (n = 3, two-way ANOVA with Sidak?s multiple comparison test, **P < 0.01, ****p < 0.0001)

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ J. Exp. Clin. Cancer Res.